Abstract
No public abstract is available from the verified source records.
Negin Salemi, Arman Rahimmi
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Treatment of amyotrophic lateral sclerosis using a gene therapy approach
1995
The genetics of amyotrophic lateral sclerosis: current insights
2016
Gene therapy for ALS: a review
10.1016/j.ymthe.2021.04.008 · 2021
C9orf72-mediated ALS and FTD: multiple pathways to disease
10.1038/s41582-018-0047-2 · 2018
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis
10.1007/s00415-024-12657-x · 2024
Nearly 30 years of animal models to study amyotrophic lateral sclerosis: a historical overview and future perspectives
10.3390/ijms222212236 · 2021
Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS
10.1038/nn.2660 · 2010
Amyotrophic lateral sclerosis
10.1056/nejmra1603471 · 2017
Gene therapy for ALS-A perspective
10.3390/ijms20184388 · 2019
Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson’s disease
10.1002/brb3.2251 · 2021
The potential of the nose-to-brain delivery of PACAP for the treatment of neuronal disease
10.3390/pharmaceutics15082032 · 2023
Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity
10.1038/mt.2008.60 · 2008
Unresolved referenced work
Kept as external metadata until matched
TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro
10.1186/s12916-024-03314-1 · 2024
Prognostic factors and epidemiology of amyotrophic lateral sclerosis in Southeastern United States
10.1016/j.mayocpiqo.2024.07.008 · 2024
Gene therapy in amyotrophic lateral sclerosis
10.3390/cells11132066 · 2022
Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent
10.1038/s41591-018-0140-5 · 2018
Advances and challenges in gene therapy for neurodegenerative diseases: a systematic review
10.3390/ijms252312485 · 2024
Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis
10.1126/scitranslmed.aai7866 · 2017
Prospects for gene replacement therapies in amyotrophic lateral sclerosis
10.1038/s41582-022-00751-5 · 2023
Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials
10.14336/ad.2013.0400295 · 2013
Beta2-adrenergic suppression of neuroinflammation in treatment of parkinsonism, with relevance for neurodegenerative and neoplastic disorders
10.3390/biomedicines12081720 · 2024
Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs
10.1016/j.neuron.2016.04.006 · 2016
Improving clinical trial outcomes in amyotrophic lateral sclerosis
10.1038/s41582-020-00434-z · 2021
Effects of noninvasive ventilation in amyotrophic lateral sclerosis: the complication of bulbar impairment
10.1177/2514183x20914183 · 2020
DNA damage, defective DNA repair, and neurodegeneration in amyotrophic lateral sclerosis
10.3389/fnagi.2022.786420 · 2022
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis
10.1038/s41591-021-01615-z · 2022
Pain in amyotrophic lateral sclerosis: a narrative review
10.12701/jyms.2022.00332 · 2022
Gene therapy in ALS and SMA: advances, challenges and perspectives
10.3390/ijms24021130 · 2023
Fly for ALS: drosophila modeling on the route to amyotrophic lateral sclerosis modifiers
10.1007/s00018-021-03905-8 · 2021
Therapeutic targeting of ALS pathways: refocusing an incomplete picture
10.1002/acn3.51887 · 2023
Amyotrophic lateral sclerosis: a clinical review
10.1111/ene.14393 · 2020
Translating the ALS genetic revolution into therapies: a review
10.1007/s11940-024-00781-y · 2024
Amyotrophic lateral sclerosis estimated prevalence cases from 2022 to 2030, data from the national ALS registry
10.1080/21678421.2024.2447919 · 2025
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
10.1080/14660820310002601 · 2003
Trial of antisense oligonucleotide tofersen for SOD1 ALS
10.1056/nejmoa2204705 · 2022
SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS
10.1056/nejmoa2005056 · 2020
Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges
10.1186/s40035-023-00377-7 · doi-reference
Genetically modified large animal models for investigating neurodegenerative diseases
10.1186/s13578-021-00729-8 · doi-reference
The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry
10.1371/journal.pone.0027985 · doi-reference
Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS
10.1016/j.arr.2020.101121 · doi-reference
ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes
10.1038/s41467-024-51676-0 · doi-reference
Amyotrophic lateral sclerosis
10.1016/s0140-6736(17)31287-4 · doi-reference
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
10.1016/s1474-4422(24)00216-3 · doi-reference
Resting state fMRI analysis of pseudobulbar affect in amyotrophic lateral sclerosis (ALS): motor dysfunction of emotional expression
10.1007/s11682-022-00744-4 · doi-reference
Decoding ALS: from genes to mechanism
10.1038/nature20413 · doi-reference
Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy
10.1038/s10038-022-01055-8 · doi-reference
Antisense oligonucleotide therapy for neurodegenerative disease
10.1172/jci25424 · doi-reference
Cell therapy in ALS: an update on preclinical and clinical studies
10.1016/j.brainresbull.2023.01.008 · doi-reference
Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis
10.1080/14656566.2017.1319937 · doi-reference
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
10.1186/s40035-023-00380-y · doi-reference
State of play in amyotrophic lateral sclerosis genetics
10.1038/nn.3584 · doi-reference
Design and statistical innovations in a platform trial for amyotrophic lateral sclerosis
10.1002/ana.26714 · doi-reference
Emerging mechanisms of molecular pathology in ALS
10.1172/jci71601 · doi-reference
Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition
10.1186/s40478-023-01671-1 · doi-reference
Simple animal models for amyotrophic lateral sclerosis drug discovery
10.1080/17460441.2016.1196183 · doi-reference
TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis
10.1021/acschemneuro.9b00026 · doi-reference
Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis
10.1056/nejmoa1916945 · doi-reference
Pathogenesis of FUS-associated ALS and FTD: insights from rodent models
10.1186/s40478-016-0358-8 · doi-reference